ECP 2023 Final Programme

Poster Sessions a Wednesday 106 Wednesday, 13 Sept PS-24 003 Moving away from reliance on formalin fixed paraffin embedded tissue- can we use circulating tumour DNA to identify driver mutations in diffuse large B-cell lymphoma? Natasha Helen Cutmore, United Kingdom I. Moutsopoulos, J. Krupka, C. Trethewey, S. Anand, L. Raso-Barnett, D. Hodson 004 Performance evaluation of different genomic testing workflows for the detection of gene-fusions in non-small cell lung cancer Jennifer Fairley, United Kingdom M. Gupta, I. Simon, S. Deans 005 Development of a novel metric to measure genomic instability using unbalanced copy number changes with fast comprehensive genomic profiling Philip Jermann, Switzerland M. Gupta, P. Jermann, G. Lowman, D. Cyanam, E. Norris, V. Mittal, S. Bandla, Y. Jin, M. Torro, L. Pickle, P. Williams, E. Wong-Ho, S. Sadis, J. Costa 006 17p13 deletions are a feature of p53 null phenotype in urothelial bladder cancer and is associated with an aggressive tumour phenotype Martina Kluth, Germany M. Hitzschke, H. Plage, M. Lennartz, N. Blessin, A. Marx, M. Fisch, M. Slojewski, T. Ecke, S. Koch, G. Sauter, T. Klatte, T. Schlomm, D. Horst, H. Zecha 007 Performance of microsatellite instability detection using Elio Tissue Complete and Idylla platforms in endometrial cancer João Lobo, Portugal M. Hanbazazh, D. Shimoga Chandrashekar, S. Harada, A. Mackinnon 008 Prognostic significance of epithelial-mesen- chymal transition (EMT) markers in stage I-III colorectal cancer Amna Matly, United Kingdom P. Hatthakarnkul, A. Ammar, M. McFarlane, J. Quinn, N. Maka, J. Park, K. Pennel, J. Edwards 009 Next Generation Sequencing bile study as a pathological diagnostic tool for early diagnosis of cholangiocarcinomas Maria Del Rosario Mercado Gutierrez, Spain I. Amat, M. Arechederra, M. Rullan, P. Azcue, I. Fernández De Los Reyes, D. Guerrero, B. Carmen, M. Avila, A. Córdoba 010 BC-miR: monitoring breast cancer-related miRNA profile in blood sera – a prosperous approach for tumour detection Tibor Pankotai, Hungary B. Borsos, Z. Páhi, Z. Újfaludi, F. Sükösd, S. Bankó, G. Pankotai-Bodó, O. Olah-Nemeth 011 Novel kinase-activating fusions in lung adenocarcinomas Grigorii Raskin, Russia E. Preobrazhenskaya, F. Zagrebin, R. Mulkidzhan, E. Saitova, I. Bizin, E. Imyanitov 012 Clinical validation of NTRK gene fusion companion diagnostics (CDx) claims for TruSightTM Oncology Comprehensive (EU) assay Victor Sementchenko, USA M. Harris, D. Vavrek, A. Martinez, C. Chen, K. Shen, L. Yun, T. Pawlowski 013 Lung cancer molecular approach by NGS/ MPS: the experience of IAP-PM using different NGS platforms Vitor Sousa, Portugal A. Ladeirinha, A. Alarcão, M. Silva, T. Ferreira, C. Eliseu, M. Viseu, V. Almeida, R. Almeida, G. Fontinha, L. Carvalho 014 Assessment of serum miRNA profiling in metastatic testicular cancer Zsuzsanna Újfaludi, Hungary F. Fazekas, T. Beöthe, T. Pankotai